XML 50 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Stockholders Equity and StockBased Compensation (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 05, 2025
Apr. 03, 2025
Mar. 12, 2025
Dec. 04, 2024
Sep. 26, 2025
Aug. 29, 2025
Aug. 28, 2025
May 23, 2025
Feb. 27, 2025
Feb. 26, 2025
Nov. 22, 2024
Aug. 19, 2024
Mar. 29, 2024
Feb. 27, 2024
Nov. 20, 2023
May 28, 2019
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
May 08, 2025
Options outstanding, granted                                     12,418 71,330    
Exercise price lower range limit                                     $ 6.85 $ 1.19    
Weighted average fair value per share at grant date                                     $ 10.33 $ 2.91    
Stock-based compensation expense                                     $ 3,746,642 $ 1,280,403    
Common stock, shares issued                                 30,384,981   30,384,981   18,783,912  
Unrecognized compensation cost related to option awards                                 $ 47,813 $ 47,853 $ 47,813 $ 47,853    
Unrecognized compensation cost related to option awards vesting period                                     2 years 3 months 3 days 2 years 3 months 3 days    
Proceeds from stock option exercise                                     $ 1,243,794 $ 0    
Description of common Stock and common stock equivalents outstanding                                     the Company had a total of 30,648,611 shares of common stock and common stock equivalents outstanding, comprised of 30,384,981 common shares outstanding (including outstanding RSAs totaling 2,113,036 shares) and stock options to purchase 263,630 shares of common stock (of which 250,547 stock options were vested).   the Company had a total of 19,248,852 shares of common stock and common stock equivalents outstanding, comprised of 18,783,912 common shares outstanding (including outstanding RSAs totaling 781,864 shares) and stock options to purchase 464,940 shares of common stock (of which 445,275 stock options were vested).  
Common stock, shares authorized                                 100,000,000   100,000,000   100,000,000  
ATM agreement amendment, description                               Under this amended agreement, the Company paid Stifel a commission equal to 3.0% of the aggregate gross proceeds of any sales of common stock under the agreement            
Shares of common stock issued 75,000,000.0       75,000,000.0     150,000,000.0                            
Consulting expense                                 $ 5,204,200 $ 2,974,810 $ 14,492,624 $ 8,858,603    
Fair value of the company's common stock per share                                 $ 21.21 $ 2.80 $ 21.21 $ 2.80    
Fair value of the Company's common stock per share                                 $ 19.28   $ 19.28   $ 16.24  
Offering price, ATM                     $ 45,000,000.0                      
Description related to ATM offerings                         The Company filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC) on March 29, 2024, registering the sale of up to $75.0 million of the Company’s securities that was declared effective on April 19, 2024. On May 10, 2024, the Company filed a prospectus supplement, which was further supplemented on July 19, 2024 and August 9, 2024 (collectively, the First Prospectus Supplement), pursuant to which the Company offered and sold shares of common stock having an aggregate offering price of up to $12.6 million from time to time through an ATM offering. The Company exhausted all capacity under the First Prospectus Supplement                  
Series X Preferred Stock [Member]                                            
Description of subscription and investment representation agreement                 (1) share of the Company’s Series X Preferred Stock, par value $0.001 per share (the Series X Preferred Stock), to the Purchaser for $100 in cash. The sale closed on February 27, 2025 and the $100 was received by the Company. The Company redeemed the Series X Preferred Stock for $100 cash after the Annual Meeting and filed the Certificate of Withdrawal with the Secretary of State of Nevada on May 8, 2025                          
Preferred stock voting rights shares                 25,000,000                          
Board of Directors Chairman [Member]                                            
Common shares issuances equity grant value       $ 500,000   $ 300,000           $ 180,000     $ 240,000              
Number of shares granted       85,915               71,713     60,456              
Common shares equity grant price per shares       $ 5.82                     $ 3.97              
Compensation cost recognized           $ 300,000           $ 180,000                    
Consulting expense                                     $ 25,000      
Common stock, valued grant date price per share           $ 15.13           $ 2.51                    
Prepaid Expenses And Other Current Assets [Member]                                            
Unrecognized compensation cost related to option awards                                 $ 275,000   $ 275,000      
Unrecognized compensation cost related to option awards vesting period                                     11 months 1 day      
Common Share Issuances [Member]                                            
Weighted average fair value per share at grant date                                     $ 7.14 $ 3.41    
Stock-based compensation expense                                     $ 15,000      
Shares of common stock issued                                     6,302 13,201    
Options [Member]                                            
Proceeds from stock option exercise                                 $ 600,000   $ 1,200,000      
Proceeds from stock options, shares                                 96,141   195,855      
Restricted Stock Award [Member]                                            
Shares, granted                                     1,467,940      
Weighted average fair value per share at grant date                                     $ 6.10      
Shares, vested                                     136,768      
Weighted average fair value grant date, granted                                     $ 13.50      
Restricted Stock Award [Member] | Board of Directors [Member]                                            
Stock-based compensation expense                                 $ 10,000   $ 400,000      
Restricted Stock Units R S A [Member] | Board of Directors Chairman [Member]                                            
Shares, granted     57,940                               57,940      
Stock-based compensation expense                                 400,000   $ 600,000      
Restricted stock awards granted   300,000                                        
Shares, vested                                     43,455      
Stock price per share   $ 6.99                                        
Restricted stock awards shares value   $ 2,100,000                                        
Weighted average fair value grant date, granted                                     $ 8.63      
Unrecognized compensation cost related to option awards                                 $ 20,500,000 $ 1,450,000 $ 20,500,000 $ 1,450,000    
Unrecognized compensation cost related to option awards vesting period                                     2 years 6 months 25 days 1 year 7 months 20 days    
RSAs vested                                     1,300,000 0    
Fair value of the Company's common stock per share                                 $ 21.21   $ 21.21      
Restricted Stock Awards Program [Member]                                            
Options outstanding, granted             1,100,000                              
Weighted average fair value per share at grant date             $ 15.54                       $ 85,000      
Stock-based compensation expense                                     $ 400,000      
Share-Based compensation arrangement, restricted stock authorized             1,800,000                              
Share-Based compensation arrangement, restricted stock grant-date fair value             $ 17,100,000                              
Restricted stock awards granted             275,000                              
Performance-based restricted stock awards granted             825,000                              
Share-based compensation arrangement by share-based payment award, grant-date fair value             $ 12,800,000                              
2025 Transactions [Member]                                            
Stock-based compensation expense                                     500,000      
Total fair value                                     $ 300,000      
Shares, vested                                     70,710      
RSA Summary 2025 and 2024 [Member]                                            
Stock-based compensation expense                                 $ 1,600,000 $ 400,000 $ 3,200,000 $ 1,100,000    
Common stock, shares issued                                 2,113,036   2,113,036   781,864  
Common stock, shares outstanding                                 2,113,036   2,113,036   781,864  
Fair value of the RSAs vested                                     $ 500,000      
First Tranche [Member]                                            
Number of shares granted under share-based payment arrangement             275,000                              
Fair value of share-based awards granted             $ 4,300,000                              
Second Tranche [Member]                                            
Number of shares granted under share-based payment arrangement             825,000                              
2020 Equity Incentive Plan [Member]                                            
Total number of common stock available for future issuance                                 2,008,361 1,471,026 2,008,361 1,471,026    
Description of equity incentive plan                   the Company’s Board of Directors approved an increase of 2,500,000 shares to the authorized number of shares under the 2020 Plan, increasing the total authorized number of shares from 2,500,000 to 5,000,000       the Board of Directors approved an increase of 700,000 shares to the authorized number of shares under the 2020 Plan, increasing the total authorized number of shares from 1,800,000 shares to 2,500,000 shares                
Maximum [Member] | Board of Directors [Member]                                            
Common stock, shares authorized                                           25,000,000
Minimum [Member] | Board of Directors [Member]                                            
Common stock, shares authorized                                           100,000,000
Available for sale Securities [Member]                                            
Proceeds from sale of common stock, shares                                 3,612,403 608,690 9,854,669 1,436,821    
Net proceeds from stock issuance under ATM                                 $ 57,300,000 $ 1,500,000 $ 120,400,000 $ 3,700,000    
Stock issuence cost                                 $ 2,000,000.0 $ 100,000 $ 4,200,000 $ 400,000